State University of New York at Buffalo
buffalo.eduTotal trials
280
Active
73
Phase 3
14
Total enrollment
41,901
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methylprednisolone 4Mg Tab | — | — | — | — | — | 1 | |
| Acetaminophen 500Mg Tab | — | — | — | — | — | 1 | |
| Ibuprofen 200Mg Oral | — | — | — | — | — | 1 | |
| Insulin | — | — | — | — | — | 1 | |
| Semaglutide | — | — | — | — | — | 1 | |
| Dapagliflozin | — | — | — | — | — | 1 | |
| Oral Ondansetron | — | — | — | — | — | 1 | |
| Combination Nicotine Replacement Therapy | — | — | — | — | — | 1 | |
| Ketamine + Lidocaine | — | — | — | — | — | 1 | |
| Ketamine group | — | — | — | — | — | 1 | |
| Fentanyl | — | — | — | — | — | 1 | |
| Bicalutamide in combination with Sunitinib | — | — | — | — | — | 1 | |
| Abaloparatide | — | — | — | — | — | 1 | |
| metformin | — | — | — | — | — | 1 | |
| Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY] | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2026-01-31
- 2026-06-30
- 2026-07-01
- 2026-07-31
- 2026-08
- 2026-08-22
- 2027-01-01
- 2028-06-01
Top conditions
- Multiple Sclerosis10
- Hyperthermia9
- Obesity8
- Pediatric Obesity7
- Diabetes Mellitus, Type 27
- Fatigue5
- Type 2 Diabetes5
- Glaucoma4
Frequently asked questions about State University of New York at Buffalo
- How many clinical trials does State University of New York at Buffalo have on ClinicalTrials.gov?
- State University of New York at Buffalo is listed as the lead sponsor on 280 clinical trials in ClinicalTrials.gov, 73 of which are currently active (recruiting, enrolling, or ongoing).
- How many of State University of New York at Buffalo's trials are in Phase 3?
- 14 of State University of New York at Buffalo's trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does State University of New York at Buffalo focus on?
- State University of New York at Buffalo's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Hyperthermia, Obesity, Pediatric Obesity, Diabetes Mellitus, Type 2.
- When are State University of New York at Buffalo's next clinical trial readouts?
- State University of New York at Buffalo has 9 upcoming primary-completion readouts tracked here; the soonest is “Bictegravir in the Elderly Living With HIV (BICEP)”, expected around 2024-12-31.